Drug Delivery Partnering Terms and Agreements

  • July 2014
  • -
  • Currentpartnering
  • -
  • 2550 pages

The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 2,500 links to online copies of actual drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The drug delivery technology includes the following sub-technology areas:

Drug Delivery

Bioavailability
Implanatable
Oral delivery
Rapid release
Delayed release
Parenteral
Infusion
Injectable
Pro-drug
Targeted
Tropical
Transdermal
Buccal
Inhaled
Nasal
Ocular
Rectal
Sublingual
Urogenital

The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug delivery dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms. Chapter 2 also contains case studies providing an insight into how companies enter into drug delivery dealmaking.

Chapter 3 provides a review of the leading drug delivery deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals organized by specific drug delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in drug delivery partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by drug delivery partnering company A-Z, deal type definitions and drug delivery partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of drug delivery technologies and products.

Drug Delivery Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to drug delivery trends and structure of deals entered into by leading companies worldwide.

Drug Delivery Partnering Terms and Agreements includes:

Trends in drug delivery dealmaking in the biopharma industry since 2009
Analysis of drug delivery deal structure and contract documents
Access to headline, upfront, milestone and royalty data
Case studies of real-life drug delivery deals
Access to over 2,500 drug delivery deals announced
The leading drug delivery deals by value since 2009
Most active drug delivery dealmakers since 2009
The leading drug delivery partnering resources


In Drug Delivery Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table Of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in drug delivery dealmaking

2.1. Introduction
2.2. Drug delivery partnering over the years
2.3. Big pharma drug delivery dealmaking activity
2.4. Big biotech drug delivery dealmaking activity
2.5. Most active drug delivery dealmakers
2.6 Drug delivery partnering by deal type
2.7. Drug delivery partnering by disease type
2.8. Partnering by drug delivery technology type
2.9. Average deal terms for drug delivery partnering
2.9.1 Drug delivery headline values
2.9.2 Drug delivery upfront payments
2.9.3 Drug delivery milestone payments
2.9.4 Drug delivery royalty rates
2.10. The anatomy of drug delivery partnering
2.11. Drug delivery or specialty pharma?
2.11.1. Is specialty pharma the only way for drug delivery?
2.11.2. Best practice for optimizing drug delivery program development
2.11.3. The anatomy of a drug delivery deal
2.11.3. a. Case study 1: Uluru - Oradisc
2.11.3.b. Case study 2: Bayer - MDRNA
2.11.3.c. Case study 3: Endo Pharmaceuticals - BioDelivery Sciences

Chapter 3 - Leading drug delivery deals

3.1. Introduction
3.2. Top drug delivery deals by value

Chapter 4 - Big pharma drug delivery deals

4.1. Introduction
4.2. How to use big pharma drug delivery partnering deals
4.3. Big pharma drug delivery partnering company profiles
Abbott
Actavis
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Fresenius
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson and Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck and Co
Merck KGaA
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Ranbaxy Laboratories
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Valeant
Warner Chilcott

Chapter 5 - Big biotech drug delivery deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech drug delivery partnering company profiles
Acorda Therapeutics
Actelion
Alkermes
AMAG Pharmaceuticals
Array Biopharma
Biocon
Cangene
Cubist
Dendreon
Elan
Emergent BioSolutions
Galapagos
Ipsen
Isis Pharmaceuticals
LFB Group
Morphosys
Nektar Therapeutics
NPS Pharmaceuticals
Onyx Pharmaceuticals
PDL BioPharma
Questcor Pharmaceuticals
Regeneron Pharmaceuticals
SciClone Pharmaceuticals
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
The Medicines Company
United Therapeutics
Vertex Pharmaceuticals
ViroPharma

Chapter 6 - Drug delivery partnering contracts directory

6.1. Introduction
6.2. Company A-Z
3M
3M Drug Delivery Systems
AAIPharma Services
Abbott Laboratories
Accredo Health Group
Acelrx Pharmaceuticals
Acorda Therapeutics
Actavis
Actient Pharmaceuticals
Adeona Pharmaceuticals
Adolor
Alchemia
Aldexa Therapeutics
Alexza Pharmaceuticals
Alfacell
Alimera Sciences
Alkermes
Allergan
Allos Therapeutics
Amag Pharmaceuticals
Amarillo Biosciences
Amarin
Amgen
Amicus Therapeutics
Ampio Pharmaceuticals
Amylin Pharmaceuticals
Anesiva
Angiotech Pharmaceuticals
AP Pharma
Apricus Biosciences
Aradigm
Aristos Pharmaceuticals
Arius Pharmaceuticals
Astellas Pharma
AstraZeneca
Audeo Oncology
Auxilium Pharmaceuticals
AVI Pharma
Azur Pharma
Bausch and Lomb
Baxter International
Bayer
BIND Biosciences
BIND Therapeutics
Bio-Path
BioArray Solutions
BioCryst Pharmaceuticals
BioDelivery Sciences
Biogen Idec
BiolineRX
Biopharmex
BioSante Pharmaceuticals
Biovail
Biovail Laboratories
BioZone Laboratories
Bristol-Myers Squibb
Calando Pharmaceuticals
Caleco Pharma
Caleco Pharma Europe
Cambridge Laboratories
Caraco Pharmaceuticals
Cardinal Health
Cardium Therapeutics
Cary Pharmaceuticals
Catalent Pharma Solutions
Celladon
Cerulean Pharma
Clarus Therapeutics
Columbia Laboratories
CombinatoRx
Control Delivery Systems
Corium International
Cornerstone Therapeutics
Cortex Pharmaceuticals
Crawford Healthcare
Critical Therapeutics
Cubist Pharmaceuticals
Cumberland Pharmaceuticals
Cutanea Life Sciences
Cyclacel Pharmaceuticals
CyDex
Cypress Bioscience
Dalian Wande Electronics
Debiopharm
Dechra Pharmaceuticals
Defense Threat Reduction Agency
Dehaier Medical Systems
Department of Defense
Department of Homeland Security
DepoMed
Dey Pharma
Dipexium Pharmaceuticals
DNA Biomedical Solutions
DoctorDirectory
Dov Pharmaceutical
DPT Laboratories
Drugs for Neglected Diseases Initiative
Duoject Medical Systems
Duramed
Durect
Dyax
Echo Therapeutics
ECR Pharmaceuticals
Egalet
EKR Therapeutics
Elan
Eli Lilly
Elite Pharmaceuticals
Emisphere
Endo Pharmaceuticals
Entera Bio
Epic Pharmaceuticals
Evonik Industries
Facet Biotechnology
FasTrack Pharmaceuticals
Ferndale Pharmaceuticals
Finorga
Fleet Laboratories
Forest Laboratories
Fovea Pharmaceuticals
Genentech
Generex Biotechnology
GenVec
Ghent University
GlaxoSmithKline
Global Health Ventures
Globe Laboratories
GlobeImmune
Graceway Pharmaceuticals
Green Vision
Grifols
Hadasit Medical Research Services and Development
Halo Pharmaceutical
Halozyme Therapeutics
Hangzhou Zhencheng Pharmaceuticals
Helix BioMedix
Horizon Pharma AG
Horizon Pharma Inc
Hospira
Hunan Jiuwang Pharmaceuticals
Idenix Pharmaceuticals
Ikaria
ImaRX
Imprimis Pharmaceuticals
Inalco Biochemicals
Inalco Group
Incyte
Inovio Pharmaceuticals
Insmed Inc
Inspire Pharmaceuticals
Intas Biopharmaceuticals
IntelGenx
Intendis
InterMune
Intrexon
Ironwood Pharmaceuticals
Jagotec
Janssen Pharmaceuticals
Javelin Pharmaceuticals
Jazz Pharmaceuticals
Jiangsu Yabang Pharmaceuticals
JPI Commercial
King Pharmaceuticals
Krele Pharmaceuticals
Kunwha Pharmaceuticals
KV Pharmaceutical
Kythera Biopharmaceuticals
Ligand Pharmaceuticals
Lipocine
Lonza
Los Angeles Biomedical Research Institute
Lupin Pharmaceuticals
Mallinckrodt Pharmaceuticals
MAP Pharmaceuticals
Marina Biotech
McCoy Enterprises
McKesson
McNeil PPC
MD Anderson Cancer Center
MDRNA
Meda
Medgenics
MediciNova
Medicis Pharma
Medpace
Meiji Seika
Melinta Therapeutics
Memorial Sloan Kettering Cancer Center
Merck and Co
Merial
Merrimack Pharmaceuticals
Mglas
Microbix Biosystems
MiddleBrook Pharmaceutical
Mikah Pharma
Millennium
Mirna Therapeutics
Mist Acquisition
Monsanto
Mundipharma
Mylan Laboratories
Nastech Pharmaceutical
Nektar Therapeutics
NeurogesX
Neuromed
Neuronex
Nitec Pharma
Norgine
NovaDel Pharma
Novartis
Novasep
Novo Nordisk
Novozymes Biopharma
NuGlow Cosmaceuticals
NuPathe
Nycomed
Oculus Innovative Sciences
Omthera Pharmaceuticals
OncoSec Medical
Oradisc
Oramed Pharmaceuticals
Orexigen Therapeutics
Ortho-McNeil-Janssen Pharmaceuticals
Oso Bio Pharmaceuticals
Pacira Pharmaceuticals
Par Pharmaceutical
Patheon
PDL BioPharma
Pfizer
PharmaEngine
Pipex Pharmaceuticals
Planned Systems International (PSI)
Pozen
Prasco Laboratories
Prestige Brands
Procter and Gamble
Professional Compounding Centers of America
ProNAi Therapeutics
PSivida
Purdue Pharma
QLT
Questcor Pharmaceuticals
Quintiles
Radius Health
Receptos
Rechon Life Sciences
RedHill Biopharma
Revance Therapeutics
Rigel Pharmaceuticals
Roche
RRD International
S2 Therapeutics
Sagent Pharmaceuticals
Salix Pharmaceuticals
Sangamo BioSciences
Sankyo Pharmaceutical
Sanofi-Aventis
Sanofi
Santarus
Scolr Pharma
Scynexis
Seattle Genetics
Serenity Pharmaceuticals
Shaanxi Jiali Pharmaceuticals
Shandong Yaoshan Pharmaceuticals
Shionogi
Shire Pharmaceuticals
Sigma-Aldrich
SK Biopharmaceuticals
SkyePharma
SLA Pharma
Smiths Medical
Solvay
Southern Research Institute
Sovereign Pharmaceuticals
Spring Creek Capital
SRI International
Strakan
Strativa Pharmaceuticals
Sun Pharmaceutical
Supernus Pharmaceuticals
SurModics
SurModics Pharmaceuticals
Symphony Allegro
Takeda Pharmaceutical
Tandem Diabetes Care
Tarsa Therapeutics
Teikoku Pharma USA
Teikoku Seiyaku
Teva Pharmaceutical Industries
The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center
The Medicines Company
The Regents of the University of California
Therabel
Transcept Pharmaceuticals
Transdel Pharmaceuticals
Tranzyme Pharma
TTY Biopharm
Ultragenyx Pharmaceuticals
Uluru
Unigene Laboratories
United Therapeutics
Valeant Pharmaceuticals
Vanda Pharmaceuticals
Ventrus Biosciences
VeroScience
VetCure
Viropharma
WA 32609
Warner Chilcott
Washington Research Foundation
Watson Laboratories
Watson Pharmaceuticals
Xi’an Zaolutang Kushidai Pharmaceuticals
XTL Biopharmaceuticals
Yamasa
Zogenix
ZymoGenetics

6.3. By deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative RandD
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

6.4. By stage of development

Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory

6.5. By therapy area

Anaesthetics
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynaecology
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Orphan disease
Pediatrics
Psychiatry
Public Health
Respiratory
Sexual health

Chapter 7 - Drug delivery dealmaking by technology type

7.1. Introduction
7.2. Deals by drug delivery type
Drug delivery
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering

See accompanying volume for:

Appendices

Introduction

Appendix 1 - Directory of drug delivery deals by company A-Z 2009-2014

Appendix 2 - Directory of drug delivery deals by stage of development 2009-2014

Appendix 3 - Directory of drug delivery deals by deal type 2009-2014

Appendix 4 - Directory of drug delivery deals by therapy area 2009-2014

Appendix 5 - Drug delivery partnering resource center
Online drug delivery partnering
Drug delivery partnering events
Further reading on drug delivery dealmaking

Table of figures

Figure 1: Drug delivery partnering since 2009
Figure 2: Big pharma - top 50 - drug delivery deals 2009 to 2014
Figure 3: Big pharma drug delivery deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - drug delivery deals 2009 to 2014
Figure 5: Big biotech drug delivery deal frequency - 2009 to 2014
Figure 6: Active drug delivery dealmaking activity- 2009 to 2014
Figure 7: Drug delivery partnering by deal type since 2009
Figure 8: Drug delivery partnering by disease type since 2009
Figure 9: Drug delivery partnering by technology type since 2009
Figure 10: Drug delivery deals with a headline value
Figure 11: Drug delivery deal headline value distribution, US$million - discovery stage
Figure 12: Drug delivery deal headline value distribution, US$million - preclinical stage
Figure 13: Drug delivery deal headline value distribution, US$million - phase I stage
Figure 14: Drug delivery deal headline value distribution, US$million - phase II stage
Figure 15: Drug delivery deal headline value distribution, US$million - phase III stage
Figure 16: Drug delivery deal headline value distribution, US$million - regulatory stage
Figure 17: Drug delivery deal headline value distribution, US$million - marketed stage
Figure 18: Summary median headline value by stage of development, 2009-2014
Figure 19: Drug delivery deals with upfront payment values
Figure 20: Drug delivery deal upfront payment distribution, US$million - discovery stage
Figure 21: Drug delivery deal upfront payment distribution, US$million - preclinical stage
Figure 22: Drug delivery deal upfront payment distribution, US$million - phase I stage
Figure 23: Drug delivery deal upfront payment distribution, US$million - phase II stage
Figure 24: Drug delivery deal upfront payment distribution, US$million - phase III stage
Figure 25: Drug delivery deal upfront payment distribution, US$million - regulatory stage
Figure 26: Drug delivery deal upfront payment distribution, US$million - marketed stage
Figure 27: Summary median upfront payments by stage of development, 2009-2014
Figure 28: Drug delivery deals with milestone payments
Figure 29: Drug delivery deal milestone distribution, US$million - discovery stage
Figure 30: Drug delivery deal milestone distribution, US$million - preclinical stage
Figure 31: Drug delivery deal milestone distribution, US$million - phase I stage
Figure 32: Drug delivery deal milestone distribution, US$million - phase II stage
Figure 33: Drug delivery deal milestone distribution, US$million - phase III stage
Figure 34: Drug delivery deal milestone distribution, US$million - regulatory stage
Figure 35: Drug delivery deal milestone distribution, US$million - marketed stage
Figure 36: Drug delivery deals with royalty rates, %
Figure 37: Drug delivery deal royalty rate distribution, US$million - discovery stage
Figure 38: Drug delivery deal royalty rate distribution, US$million - preclinical stage
Figure 39: Drug delivery deal royalty rate distribution, US$million - phase I stage
Figure 40: Drug delivery deal royalty rate distribution, US$million - phase II stage
Figure 41: Drug delivery deal royalty rate distribution, US$million - phase III stage
Figure 42: Drug delivery deal royalty rate distribution, US$million - regulatory stage
Figure 43: Drug delivery deal royalty rate distribution, US$million - marketed stage
Figure 44: Summary median royalty rate by stage of development, 2009-2014
Figure 45: Components of the typical drug delivery deal structure
Figure 46: Best practice for drug delivery program development
Figure 47: Top drug delivery deals by value since 2009

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

RNAi Drug Delivery : Technologies and Gobal Markets

RNAi Drug Delivery : Technologies and Gobal Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research report provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious ...

Lyophilization Market by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, & Others), Technology (Tray-style, Manifold, & Rotary) & Geography - Global Trends & Forecast to 2019

Lyophilization Market by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, & Others), Technology (Tray-style, Manifold, & Rotary) & Geography - Global Trends & Forecast to 2019

  • $ 4 650
  • Industry report
  • September 2014
  • by MarketsandMarkets

Lyophilization or freeze-drying has significant applications in the food, pharmaceutical, and biotechnology industry and is used as a standard process to stabilize, store, and increase the shelf-life of ...

Global Transdermal Drug Delivery Market 2014-2018

Global Transdermal Drug Delivery Market 2014-2018

  • $ 2 500
  • Industry report
  • June 2014
  • by Infiniti Research Limited

About Transdermal Drug Delivery Transdermal drug delivery is a large and growing vertical market of the Pharmaceutical industry. Transdermal drug delivery is defined as a system that utilizes skin as a ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.